The CFPC’s Relationship With the Health Care and Pharmaceutical Industry
CFPC 2020 HPI Report
The CFPC is pleased to provide the 2020 report on its continued management of working relationships with the Health Care/Pharmaceutical Industry (HPI). The current report provides data and highlights from 2018/2019. Read the 2020 HPI Report.
October 2019
CFPC
Members provided feedback on two questions: 1. What is your level of support for discontinuing HPI exhibitors from FMF over the next three to five years? 2. What is your level of support for a potential future increase in annual CFPC membership fees (approximately $50 annually for an Active member) to offset the loss of HPI revenues at FMF, if cost-saving measures are not enough? Comments shared by responding members are also included.
January 2019
CFPC
Management of Relationships With the Health Care/Pharmaceutical Industry
The January 2019 report entitled Management of Relationships with the Healthcare/Pharmaceutical Industry includes information on this important issue for the CFPC’s fiscal years 2016–2017 and 2017–2018. Following the 2013 Task Force report, the CFPC Board further mandated that the College report regularly on the implementation of the approved recommendations in the areas of continuing professional development (CPD), Family Medicine Forum (FMF), and Canadian Family Physician (CFP).
August 2013
CFPC
The CFPC’s Relationship With the Health Care/Pharmaceutical Industry
In 2010 the College of Family Physicians of Canada (CFPC) established the Task Force on the CFPC’s Relationship with the Health Care/Pharmaceutical Industry (HPI) to review and make recommendations about the College’s relationship with the HPI. HPI’s ability to influence the decision making of family physicians with respect to patient care through its relationship with the CFPC makes it important for the College to have clear, well-defined policies and practices to appropriately guide its working relationships with the HPI. The review included all for‐profit entities that develop, produce, market, or distribute drugs, devices, products, services, or therapies that may be prescribed or ordered by doctors for their patients to diagnose, treat, monitor, manage, and alleviate health conditions.
